Norway · Delayed Price · Currency is NOK Vistin Pharma ASA Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw stable revenue and profit, with strong sales volume offset by currency and price pressures. Safety stock and a renewable energy deal mitigate supply risks, while a planned Q4 maintenance stop will temporarily impact output. Dividend of up to NOK 1.5/share proposed.
Fiscal Year 2025
-
Q4 2025 saw record sales volume and a 5% revenue increase for the year, but lower metformin prices led to a Q4 revenue decline. Full-year EBITDA and net profit reached all-time highs, with strong margins and a proposed NOK 1.5 per share dividend.
-
Q3 2025 saw 3% revenue growth and a 10% sales volume increase, with EBITDA at NOK 28 million and net profit up year-over-year. Production hit a record 1,600 metric tons, and the company remains focused on ramping capacity and maintaining strong margins amid stable demand and favorable market trends.
-
Q2 2025 saw 11% revenue and EBITDA growth, driven by record sales volumes and strong gross margins. Market demand for metformin remains robust, with ongoing capacity expansion and stable operational performance.
-
Revenue grew 11% and EBITDA rose 48% year-over-year, driven by strong demand, higher sales volume, and operational improvements. Gross margin reached 62%, and net profit nearly tripled. The company maintains a strong balance sheet, proposes a NOK 1.25 dividend, and expects continued market growth.
Fiscal Year 2024
-
Q4 2024 saw revenue and EBITDA growth driven by higher sales volumes and strong cost control, with full-year EBITDA reaching a record NOK 104 million. The company maintains a robust balance sheet, proposes a higher dividend, and expects continued growth as global metformin demand rises.
-
Q3 2024 saw record EBITDA and gross margin despite lower revenue and sales volume, with strong operational performance and no interest-bearing debt. The Metformin market outlook remains robust, supported by global diabetes trends and strategic investments in sustainability and growth.
-
Q2 2024 saw record EBITDA and strong gross margins, with stable revenue and higher sales volume despite global price pressures. Strategic investments, dividend payouts, and a focus on sustainability position the company for continued growth in a rising metformin market.